Diabetes Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight
(Albany, USA) DelveInsight's, ' Diabetes Pipeline Insight 2025 ' report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook
Key Takeaways from the Diabetes Pipeline Report
In April 2025, Gan & LEE Pharmaceuticals announced a study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.
In March 2025, Dong-AST Co. Ltd announced a study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control.
In March 2025, Novo Nordisk A/S announced a study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine doctors can already prescribe). Participants will either get faster aspart or insulin aspart (NovoRapid®) - which treatment is decided by chance.
DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
The leading Diabetes Companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others.
Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs
Emerging Diabetes Drugs Profile
Cadisegliatin: vTv Therapeutics
Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Diabetes.
LY-3209590: Eli Lilly and Company
Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.
THDB0206: Tonghua Dongbao Pharmaceutical
BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of Diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Diabetes.
CPL207280: Celon Pharma
CPL207280 is a novel G-protein-coupled receptor 40 (GPR40) agonist under development for the treatment of Diabetes. CPL207280 acts as an agonist for GPR40, a receptor that plays a crucial role in enhancing glucose-stimulated insulin secretion from pancreatic beta cells. This mechanism is particularly beneficial for T2D patients, as it can improve glycemic control without the risk of hypoglycemia, a common side effect associated with other diabetes medications. Currently, the drug is in the Phase II stage of development to treat Diabetes.
XW014: Sciwind Biosciences
XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes.
KN056: Suzhou Alphamab Co., Ltd.
KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of Diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with Diabetes. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of Diabetes.
The Diabetes Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market
Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs and Medication
Diabetes Companies
vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diabetes Products have been categorized under various Molecule types such as,
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers
Scope of the Diabetes Pipeline Report
Coverage- Global
Diabetes Companies- vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetes– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Cadisegliatin: vTv Therapeutics
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
CPL207280: Celon Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
KN056: Suzhou Alphamab Co., Ltd.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diabetes Key Companies
Diabetes Key Products
Diabetes- Unmet Needs
Diabetes- Market Drivers and Barriers
Diabetes- Future Perspectives and Conclusion
Diabetes Analyst Views
Diabetes Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 minutes ago
- Globe and Mail
As Trump's latest tariff deadline nears, here are the trade deals the U.S. has announced so far
The clock is ticking closer to U.S. President Donald Trump's latest tariff deadline of Aug 1. And while several more deals – or at least frameworks for deals – have been reached since his last tariff deadline of July 9 came and went, trade talks with many countries are still in flux. Trump unveiled sweeping import taxes on goods coming into the U.S. from nearly every country back in April. That included heightened so-called reciprocal rates for certain countries, the bulk of which have since been postponed twice. The first 90-day pause arrived in an apparent effort to quell global market panic and facilitate country-by-country negotiations, with the Trump administration at one point setting a lofty goal of reaching 90 trade deals in 90 days. But three months later, only two deals emerged: with the U.K. and Vietnam. A separate 'framework' for a deal was hashed out with China. And by early July, Trump began sending warning letters that higher tariffs would be imposed against dozens of countries on Aug. 1. Since then, the U.S. has announced more trade frameworks. But, key details remain sparse – or not immediately captured in writing. Here's what we know about the agreements so far, in the order of those most recently announced. The U.S. President said he reached an agreement with Seoul on July 30 that would impose a 15-per-cent tariff for goods from South Korea. The countries have also agreed for South Korea to buy US$100-billion in energy resources from the U.S. and for South Korea to give to the U.S. US$350-billion for 'investments owned and controlled by the United States, and selected by myself, as president,' Trump said. The U.S. and the EU announced a trade framework that imposes 15-per-cent tariffs on most European goods – warding off Trump's most recent threat of 30-per-cent if no deal had been reached by Aug. 1. But some key details require more work. The headline of the agreement, unveiled July 27, is that the 15-per-cent tariff rate will apply to 70 per cent of European goods brought into the U.S. – with the EU later confirming that that rate applies to pharmaceuticals, semiconductors, and car and car parts. But the remaining 30 per cent of those imports is still open for negotiations. European Commission President Ursula von der Leyen said that both sides had agreed to zero tariffs for a range of 'strategic' goods. Meanwhile, Trump pointed to heightened investments from European companies in the U.S. – including what Trump said was US$750-billion (€638-billion) worth of natural gas, oil and nuclear fuel over three years, as well as an additional US$600-billion (€511-billion) under a political commitment that isn't legally binding, officials said. Explainer: The details of Trump's trade deal with the EU On July 22, Trump announced a trade framework to impose 15-per-cent tariffs on Japan – down from his previously-threatened rate of 25 per cent. The U.S. President also said Japan would invest US$550-billion into the U.S. and would 'open' its economy to American autos and rice. The newly-agreed on 15-per-cent tariff rate also applies to Japanese cars – marking a welcome relief for automakers like Toyota Motor Corp. and Honda – which, like other automakers, have faced a 25-per-cent levy on key parts and finished vehicles going into the U.S. since earlier this year. But car companies in other countries, including U.S. competitors, worry that this could put them at a disadvantage. Shortly after a July 22 meeting with Philippine President Ferdinand Marcos, Jr., Trump announced that he would lower his coming tariffs on imports from the country to 19 per cent – down just 1 per cent from his previous threat of 20 per cent. In return, Trump said on Truth Social, the U.S. would not pay tariffs on American goods it shipped to the Philippines. But additional details remained unclear. Marcos said his country was considering options such as having an open market without tariffs for U.S. automobiles, but emphasized details were still left to be worked out. Explainer: What are the current tariffs between Canada and the U.S.? On July 15, Trump again took to social media to announce that he's agreed to lower his planned tariffs on Indonesian goods to 19 per cent – down from a previously-threatened levy of 32 per cent – while American goods sent to the southeast Asian country will face no tariffs. A fact sheet from the White House later confirmed that 'over 99% of U.S. products' exported to Indonesia would be sent duty-free. Indonesian President Prabowo Subianto said he will continue to negotiate with Trump, in hopes of further lowering the coming U.S. tariffs. On July 2, Trump announced a trade deal with Vietnam that he said would allow U.S. goods to enter the country duty-free. Vietnamese exports to the U.S., by contrast, would face a 20-per-cent levy. That's less than half the 46 per cent 'reciprocal' rate Trump proposed for Vietnamese goods back in April. But in addition to the new 20-per-cent tariff rate, Trump said the U.S. would impose a 40-per-cent tax on 'transshipping' – targeting goods from another country that stop in Vietnam on their way to the United States. Washington complains that Chinese goods have been dodging higher U.S. tariffs by transiting through Vietnam. On May 8, Trump agreed to cut tariffs on British autos, steel and aluminum, among other trade pledges – while the U.K. promised to reduce levies on U.S. products like olive oil, wine and sports equipment. The deal was announced in grandiose terms by both countries, but some key details remained unknown for weeks. When the deal was announced, for example, the British government notably said that the U.S. agreed to exempt the U.K. from its then-universal 25-per-cent duties on foreign steel and aluminum – which would have effectively allowed both metals from the country to come into the U.S. duty-free. But the timing for when those cuts would actually take effect stayed up in the air for almost a month. It wasn't until early June, when Trump hiked his steel and aluminum tariffs to a punishing 50 per cent worldwide, that the U.S. acknowledged it was time to implement the agreement. And even then, U.S. tariffs on British steel and aluminum did not go to zero. The U.K. was the only country spared from Trump's new 50-per-cent levies, but still faces 25-per-cent import taxes on the metals. At its peak, Trump's new tariffs on Chinese goods totalled 145 per cent – and China's countertariffs on American products reached 125 per cent. But on May 12, the countries agreed to their own 90-day truce to roll back those levies to 30 per cent and 10 per cent, respectively. And in June, details began trickling in about a tentative trade agreement. U.S. Treasury Secretary Scott Bessent said that China had agreed to make it easier for American firms to acquire Chinese magnets and rare earth minerals critical for manufacturing and microchip production. Meanwhile, the Chinese Commerce Ministry said that the U.S. would 'lift a series of restrictive measures it had imposed on China.' Other key details of the deal remain murky – including the timing of implementation for these terms. On July 29, China's top trade official said the two sides had agreed to work on extending an Aug. 12 deadline for new tariffs on each other, following a two-day trade meeting in Stockholm. The U.S. side said extension plans were discussed, but not decided.
Globe and Mail
3 minutes ago
- Globe and Mail
Meta's Earnings Streak Continues as Ad Business Performs
META Q2 Earnings Deliver the Goods Zacks Rank #1 (Strong Buy) stock Meta Platforms ( META ) crushed earnings yet again on Wednesday evening, delivering EPS of $7.14 versus estimates of $5.89 and revenue of $47.52 billion versus estimates of $44.83 billion. Currently, META shares are up ~8.5%, in line with what the market was anticipating. The top and bottom-line earnings beat again prove that META is one of the most consistent growth engines on Wall Street, with investors enjoying the company's eleventh consecutive earnings beat. With double-digit EPS and revenue growth, it's difficult for investors to find a company growing as fast, consistently, and with such liquidity as META. Because META has this rare trifecta, institutional investors are likely to continue to pile in and use it as a 'hedge fund hotel.' META Ad Business Remains Robust The most significant item investors watch for in a Meta earnings report is ads. Not only does ad revenue comprise the lion's share of Meta's revenue, it also represents how Meta's massive AI bets are actually impacting the company. Ad impressions continued to increase in Q2, as impressions jumped 11% year-over-year, helped by Meta's AI optimization efforts. Additionally, Meta is making more off these impressions, with an average price per ad increase of 9% year-over-year. Overall, the core advertising engine is firing on all cylinders, with Meta generating 22% year-over-year growth in the segment. It's clear from Meta's price action over the past few months that investors believe CEO Mark Zuckerberg's massive pivot to AI will work in the long term. As META shares break out from yet another base structure, a reasonable target into 2026 is between $900 and $1,000 per share (based on Fibonacci extensions). META: Potential Headwinds Management has guided that expense growth will accelerate next year with a substantial CAPEX increase, potentially impacting margins negatively. Additionally, Meta's 'Reality Labs' segment continues to hemorrhage cash, continuing a troubling trend and costing the company $4.5 billion. While Reality Labs' poor financial performance is something for investors to watch, it is merely a drop in the bucket of Meta's massive business, and investors should mainly focus their attention on Meta's core ad business. META: What to Look for Moving Forward From a CAPEX spending perspective, META is among the companies making the most aggressive bets on AI. CAPEX is expected to increase yet again next quarter. Thus far, investors are applauding the bold strategy and aggressive spending. That said, investors will want to continue to see strong earnings as a result. Bottom Line Meta Platforms continues to demonstrate exceptional financial performance, driven by its robust ad business and significant AI investments. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Meta Platforms, Inc. (META): Free Stock Analysis Report
Globe and Mail
3 minutes ago
- Globe and Mail
Alcoa Corporation Declares Quarterly Cash Dividend
Alcoa Corporation (NYSE: AA; ASX: AAI) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 per share of the Company's common stock and Series A convertible preferred stock, to be paid on August 28, 2025 to stockholders of record as of the close of business on August 12, 2025. About Alcoa Corporation Alcoa is a global industry leader in bauxite, alumina and aluminum products with a vision to build a legacy of excellence for future generations. With a values-based approach that encompasses integrity, operating excellence, care for people, and courageous leadership, our purpose is to Turn Raw Potential into Real Progress. Since developing the process that made aluminum an affordable and vital part of modern life, our talented Alcoans have developed breakthrough innovations and best practices that have led to greater efficiency, safety, sustainability, and stronger communities wherever we operate. Dissemination of Company Information Alcoa intends to make future announcements regarding company developments and financial performance through its website, as well as through press releases, filings with the Securities and Exchange Commission, conference calls, media broadcasts, and webcasts. The Company does not incorporate the information contained on, or accessible through, its corporate website into this press release.
